OncoSil Medical Randomizes First South Australia Patient in Pancreatic Cancer Clinical Trial; Shares Up 17%

MT Newswires Live

2024/12/31

OncoSil Medical (ASX:OSL) randomized the first patient at Royal Adelaide Hospital in South Australia for the TRIPP-FFX clinical trial for pancreatic cancer treatment, marking the start of patient recruitment at the hospital, according to a Tuesday filing with the Australian bourse.

The trial aims to evaluate the safety and effectiveness of the OncoSil device in conjunction with Folfirinox chemotherapy, the filing said.

Royal Adelaide Hospital's first randomized patient has increased the global TRIPP-FFX trial enrollment to 49, according to the filing.

Shares rose nearly 17% in morning trade Tuesday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2495885685"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2495885685\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2495885685?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-31 08:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2495885685","market":"sg","top_or_hot":-1,"title":"OncoSil Medical Randomizes First South Australia Patient in Pancreatic Cancer Clinical Trial; Shares Up 17%","media":"MT Newswires Live","content":"<html><body><p> OncoSil Medical (ASX:OSL) randomized the first patient at Royal Adelaide Hospital in South Australia for the TRIPP-FFX clinical trial for pancreatic cancer treatment, marking the start of patient recruitment at the hospital, according to a Tuesday filing with the Australian bourse.</p><p>The trial aims to evaluate the safety and effectiveness of the OncoSil device in conjunction with Folfirinox chemotherapy, the filing said.</p><p>Royal Adelaide Hospital's first randomized patient has increased the global TRIPP-FFX trial enrollment to 49, according to the filing.</p><p>Shares rose nearly 17% in morning trade Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OncoSil Medical Randomizes First South Australia Patient in Pancreatic Cancer Clinical Trial; Shares Up 17%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOncoSil Medical Randomizes First South Australia Patient in Pancreatic Cancer Clinical Trial; Shares Up 17%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-31 08:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> OncoSil Medical (ASX:OSL) randomized the first patient at Royal Adelaide Hospital in South Australia for the TRIPP-FFX clinical trial for pancreatic cancer treatment, marking the start of patient recruitment at the hospital, according to a Tuesday filing with the Australian bourse.</p><p>The trial aims to evaluate the safety and effectiveness of the OncoSil device in conjunction with Folfirinox chemotherapy, the filing said.</p><p>Royal Adelaide Hospital's first randomized patient has increased the global TRIPP-FFX trial enrollment to 49, according to the filing.</p><p>Shares rose nearly 17% in morning trade Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2495885685","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2495885685","pubTimestamp":1735605198,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"OncoSil Medical  randomized the first patient at Royal Adelaide Hospital in South Australia for the TRIPP-FFX clinical trial for pancreatic cancer treatment, marking the start of patient recruitment at the hospital, according to a Tuesday filing with the Australian bourse.The trial aims to evaluate the safety and effectiveness of the OncoSil device in conjunction with Folfirinox chemotherapy, the filing said.Royal Adelaide Hospital's first randomized patient has increased the global TRIPP-FFX trial enrollment to 49, according to the filing.Shares rose nearly 17% in morning trade Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","XKO.AU":"标普/澳交所 300指数","XJO.AU":"标普/澳交所 200指数","BK7048":"生命科学工具和服务","OSL.AU":"ONCOSIL MEDICAL LTD","XAO.AU":"标普/澳交所 普通股指数"},"translate_title":"OncoSil Medical在胰腺癌临床试验中随机分配首例南澳大利亚患者；股价上涨17%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSL.AU":0.9,"XJO.AU":1,"XKO.AU":1,"XAO.AU":1},"content_text":"OncoSil Medical (ASX:OSL) randomized the first patient at Royal Adelaide Hospital in South Australia for the TRIPP-FFX clinical trial for pancreatic cancer treatment, marking the start of patient recruitment at the hospital, according to a Tuesday filing with the Australian bourse.The trial aims to evaluate the safety and effectiveness of the OncoSil device in conjunction with Folfirinox chemotherapy, the filing said.Royal Adelaide Hospital's first randomized patient has increased the global TRIPP-FFX trial enrollment to 49, according to the filing.Shares rose nearly 17% in morning trade Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}